中国全科医学2026，Vol.29Issue(22)：3079-3085,7.DOI:10.12114/j.issn.1007-9572.2026.0006
BMJ《SGLT-2抑制剂用于成人慢性肾脏病患者临床实践指南》解读
Interpretation of BMJ Clinical Practice Guideline:SGLT-2 Inhibitors for Adults with Chronic Kidney Disease
摘要
Abstract
The clinical practice guideline on the use of sodium-glucose cotransporter 2(SGLT-2)inhibitors in adult patients with chronic kidney disease(CKD),published in the BMJ in October 2024,stratifies patients with CKD into four risk tiers-low,moderate,high,and very high-based on estimated glomerular filtration rate(eGFR)and proteinuria levels to assess their risk of complications and disease progression.The guideline provides a quantitative evaluation of the benefits and risks of SGLT-2 inhibitors across different risk tiers and proposes a tiered recommendation strategy.For instance,for adult patients with CKD who have a low or moderate risk of disease progression and complications,the use of SGLT-2 inhibitors can be considered(weak recommendation);whereas for those with a high or very high risk,the use of SGLT-2 inhibitors is recommended(strong recommendation).This approach supports individualized decision-making for patients and assists general practitioners in the rational and standardized use of SGLT-2 inhibitors across diverse clinical settings.Additionally,the guideline's rapid-access web version offers highly visualized evidence and recommendation presentation tools,facilitating quick reference for general practitioners and supporting the implementation of shared decision-making between clinicians and patients.关键词
钠-葡萄糖共转运蛋白 2 抑制剂/慢性肾脏疾病/风险分级/诊疗指南/医患共同决策Key words
Sodium-glucose transporter 2 inhibitors/Chronic kidney disease/Risk stratification/Diagnostic and treatment guideline/Physician-patient shared decision-making分类
医药卫生引用本文复制引用
瞿芙容,赵黎君,曾筱茜,李静,李舍予..BMJ《SGLT-2抑制剂用于成人慢性肾脏病患者临床实践指南》解读[J].中国全科医学,2026,29(22):3079-3085,7.基金项目
癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项(2024ZD0532000,2024ZD0532003) （2024ZD0532000,2024ZD0532003）
